Treatment of Small Cell Lung Cancer in the Elderly
Open Access
- 1 June 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 10 (6), 399-411
- https://doi.org/10.1634/theoncologist.10-6-399
Abstract
Small cell lung cancer (SCLC) accounts for approximately 20% of lung carcinomas. Chemotherapy is the cornerstone of treatment for SCLC. In limited disease, the median survival time is about 12–16 months, with a 4%–5% long-term survival rate; in extensive disease the median survival time is 7–11 months. More than 50% of lung cancer patients are diagnosed when they are over the age of 65, and about 30% are over 70. Elderly patients tolerate chemotherapy poorly compared with their younger counterparts, because of age-related progressive reductions in organ function and comorbidities. The standard therapy for limited disease is combined chemoradiotherapy, followed by prophylactic brain irradiation for patients achieving complete responses. In the elderly, the addition of radiotherapy to chemotherapy must be carefully evaluated, considering the slight survival benefit and potential for substantial toxicity incurred with this treatment. The best approach is to design clinical trials that specifically include geriatric assessment to develop active and well-tolerated chemotherapy regimens for elderly SCLC patients. Survival improvement for SCLC patients requires a better understanding of tumor biology and the subsequent development of novel therapeutic strategies. Several targeted agents have been introduced into clinical trials in SCLC, but a minority of these new agents offers a promise of improved outcomes, and negative results are reported more commonly than positive ones. This review focuses on the main issues in the treatment of elderly SCLC patients.Keywords
This publication has 77 references indexed in Scilit:
- Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age ≥ 70 YearsJournal of Clinical Oncology, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Geriatric oncologyEuropean Journal Of Cancer, 2000
- Lung cancer in the elderlyEuropean Journal Of Cancer, 1997
- 88 Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC): Preliminary results of a randomized studyLung Cancer, 1997
- Epirubicin in previously untreated patients with small cell lung cancer: A phase II study by the EORTC lung cancer cooperative groupEuropean Journal Of Cancer, 1992
- Teniposide as single drug therapy for elderly patients affected by small cell lung cancerEuropean Journal Of Cancer, 1992
- Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means?European Journal of Cancer and Clinical Oncology, 1991
- Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)European Journal of Cancer and Clinical Oncology, 1988
- Social and Economic Factors in the Choice of Lung Cancer TreatmentNew England Journal of Medicine, 1988